Can the GLP-1 hypothesis also explain part of the efficacy demonstrated by glucagon receptor antagonist antibodies, which appear to be nearly as effective as Gcgr knockout in preventing STZ-induced hyperglycemia? The gene discussed is GCG; the disease is Hyperglycemia.